Standout Papers

Dabigatran versus Warfarin in Patients with Atrial Fibrillation 2009 2026 2014 2020 7.8k
  1. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (2009)
    Stuart J. Connolly, Michael D. Ezekowitz et al. New England Journal of Medicine
  2. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS (2016)
    Paulus Kirchhof, Stefano Benussi et al. Revista Española de Cardiología (English Edition)
  3. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (2017)
    Christopher P. Cannon, Deepak L. Bhatt et al. New England Journal of Medicine
  4. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation (2011)
    John W. Eikelboom, Lars Wallentin et al. Circulation
  5. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial (2010)
    Lars Wallentin, Salim Yusuf et al. The Lancet
  6. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation (2015)
    Hein Heidbüchel, Peter Verhamme et al. EP Europace
  7. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation (2013)
    Hein Heidbüchel, Peter Verhamme et al. EP Europace
  8. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study (2016)
    Ziad Hijazi, Jonas Oldgren et al. The Lancet
  9. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation (2016)
    Ziad Hijazi, Johan Lindbäck et al. European Heart Journal

Immediate Impact

182 standout
Sub-graph 1 of 12

Citing Papers

Stroke
2024 Standout
Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic
2023 Standout
19 intermediate papers

Works of Jonas Oldgren being referenced

Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
2022
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation
2020
and 9 more

Author Peers

Author Last Decade Papers Cites
Jonas Oldgren 18985 8105 1661 2705 193 20.9k
Paul Reilly 15327 7602 1143 2302 123 17.0k
Janice Pogue 14390 4616 1890 2821 74 18.8k
Rafael Díaz 12341 3981 2930 1906 128 17.8k
Werner Hacke 12620 5961 1017 2737 115 14.2k
Brian F. Gage 9533 3453 1811 2172 177 17.0k
Harald Darius 10699 4359 2779 1998 198 14.6k
Scott D. Berkowitz 13285 8548 3252 1864 193 16.5k
Denis Xavier 10426 4771 1525 1734 100 13.1k
Marco Alings 12486 5468 939 1925 84 13.6k
Elaine M. Hylek 23759 10794 2612 4395 252 30.2k

All Works

Loading papers...

Rankless by CCL
2026